Patents/Assignees

Ionis Pharmaceuticals, Inc.

61 patents in portfolio

US12227746utility2025
Compounds and Methods for Modulating SCN2A
0 cites
US12215321utility2025
Modulators of Diacyglycerol Acyltransferase 2 (DGAT2)
0 cites
US12188020utility2025
Methods for Reducing Ataxin-2 Expression
0 cites
US12180479utility2024
Compounds and Methods for Modulating ATXN1
0 cites
US12157890utility2024
Modulators of MALAT1 Expression
0 cites
US12152052utility2024
Compounds and Methods for Reducing MECP2 Expression
0 cites
US12152244utility2024
Selective Antisense Compounds and Uses Thereof
0 cites
US12129466utility2024
Compounds and Methods for Modulating UBE3A-ATS
0 cites
US12115225utility2024
GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
0 cites
US12110491utility2024
Selective Reduction of Allelic Variants
0 cites
US12042510utility2024
Modulators of IRF4 Expression
0 cites
US12043831utility2024
Modulation of Alpha Synuclein Expression
0 cites
US12030910utility2024
Compounds and Methods for the Modulation of Proteins
0 cites
US12018261utility2024
Compounds and Methods for Modulating Factor XII
0 cites
US11981897utility2024
Compounds and Methods for Modulation of Dystrophia Myotonica-protein Kinase (DMPK) Expression
0 cites
US11959080utility2024
Methods and Compositions for Inhibiting PMP22 Expression
0 cites
US11926830utility2024
Modulators of Complement Factor B
0 cites
US11926825utility2024
Compounds and Methods for Reducing ATXN2 Expression
0 cites
US11873495utility2024
Compounds and Methods for Reducing LRRK2 Expression
0 cites
US11859180utility2024
Antisense Oligonucleotide Compositions
0 cites

← PreviousPage 2 of 4Next →